Security key
30050B101
Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share (EVH)
CUSIP: 30050B101
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Class A Common Stock, par value $0.01 per share
- Total 13F shares
- 3,587
- Total 13F value
- $19,441
- Share change
- +3,053
- SEC-reported price per share
- $5.42
- Number of holders
- 3
- Value change
- +$16,547
- Number of buys
- 2
- Shares outstanding
- 112,318,617
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
6
EVH full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Evolent Health, Inc. SEC filings
Evolent Health, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 30050B101
Recent filing periods:
Ownership snapshot
Top reported holders of EVH - Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
CADIAN CAPITAL MANAGEMENT...
Disclosed value leader
CADIAN CAPITAL MANAGEMENT...
Comparable rows
15/15
Latest evidence
04 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.3%
13D/G row: CADIAN CAPITAL MANAGEMENT, LP
Showing 1-6 of 15 holder rows.
Quick read
CADIAN CAPITAL MANAGEMENT, LP leads the comparable SEC ownership view at 9.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens CADIAN CAPITAL MANAGEMENT, LP's linked filing trail.
Comparable ownership
Top 5
CADIAN CAPITAL MANAGEMENT, LP
9.3%
MORGAN STANLEY
8.1%
VANGUARD GROUP INC
8%
Boehler Adam
5.2%
RA CAPITAL MANAGEMENT, L.P.
3.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| CADIAN CAPITAL MANAGEMENT, LP |
13D/G
13F
Company
|
9.3%
|
$106,218,923
10,794,606 shares
|
$0 | 31 Mar 2025 |
| MORGAN STANLEY |
13D/G
13F
Company
|
8.1%
|
$37,755,903
9,097,808 shares
|
+$3,682,702 | 31 Dec 2025 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
8%
|
$35,656,260
8,914,065 shares
|
$0 | 31 Dec 2025 |
| Boehler Adam |
13D/G
Rubicon OP GP II LP
|
5.2%
|
$49,204,401
5,816,123 shares
|
$0 | 13 Nov 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
3.1%
|
$35,199,618
3,577,197 shares
|
$0 | 31 Dec 2024 |
| FMR LLC |
13D/G
|
0.7%
|
$3,003,548
750,887 shares
|
-$34,663,704 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
3,587
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
186
Q2 2026 holders
3
Holder diff
-183
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend